Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.22.2
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Non-Refundable Milestone Payment                   $ 4,000,000.0
Commercial Sales In Specified Territories | PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           $ 21,500,000   $ 21,500,000    
Neupharma                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment of upfront licensing fees         $ 1,000,000.0          
Neupharma | Additional Sales Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           40,000,000.0   40,000,000.0    
Neupharma | Clinical and Development Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           40,000,000.0   40,000,000.0    
Neupharma | Regulatory Approvals To Commercialize The Products                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           22,500,000   22,500,000    
Dana-Farber                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Number of shares of common stock granted 136,830 500,000                
Ownership percentage   5.00%                
Cash in exchange for common shares   $ 10,000,000                
Maintenance fee               50,000    
Value of common stock shares issued $ 600,000 $ 32,500                
Sale price per share   $ 0.065                
Dana-Farber | First Commercial Sale Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           21,500,000   21,500,000    
Dana-Farber | Additional Sales Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           60,000,000.0   60,000,000.0    
Jubilant Biosys Ltd                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment of upfront licensing fees       $ 2,000,000.0            
Revenue recognition milestone revenue recognized           $ 2,000 $ 55,000 $ 23,000 $ 78,000  
Proceeds from upfront fees       $ 1,000,000.0            
Research and development cost           50.00%   50.00%    
Jubilant Biosys Ltd | Clinical and Development Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           $ 89,000,000.0   $ 89,000,000.0    
Jubilant Biosys Ltd | Regulatory Approvals To Commercialize The Products                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           59,500,000   59,500,000    
Jubilant Biosys Ltd | Five Regulatory Approvals And First Commercial Sales                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           61,700,000   61,700,000    
Jubilant Biosys Ltd | Sale Millstone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           89,000,000.0   89,000,000.0    
Maximum potential milestone payments           89,000,000.0   89,000,000.0    
Jubilant Biosys Ltd | Clinical Development and Regulatory Milestones                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           87,200,000   87,200,000    
Adimab LLC | Clinical and Development Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           7,100,000   7,100,000    
Adimab LLC | Regulatory Approvals To Commercialize The Products                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           4,800,000   4,800,000    
Collaboration Agreement With TGTX                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone revenue recognized           16,000 $ 100,000 47,000 $ 145,000  
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000          
Collaboration Agreement With TGTX | First Commercial Sale Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           14,500,000   14,500,000    
Collaboration Agreement With TGTX | First Commercial Sale Milestone | PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum potential milestone payments           27,600,000   27,600,000    
Collaboration Agreement With TGTX | Clinical and Development Milestone | PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           7,000,000.0   7,000,000.0    
Collaboration Agreement With TGTX | Commercial Sales In Specified Territories | PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           19,200,000   19,200,000    
Collaboration Agreement With TGTX | Clinical Development and Regulatory Milestones | PD-L1                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           8,400,000   8,400,000    
Sublicense Agreement with TGTX | Clinical and Development Milestone                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue recognition milestone payments           $ 25,500,000   $ 25,500,000